Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $177.50 short call and a strike $182.50 long call offers a potential 25.94% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $177.50 by expiration. The full premium credit of $1.03 would be kept by the premium seller. The risk of $3.97 would be incurred if the stock rose above the $182.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 25.23 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Raising the White Flag on Allergan: Best of Kass
Mon, 06 Nov 2017 06:00:00 +0000
In highlights from this week's trading diary and posts, Kass finally just gives up on Allergan.
Action Alerts PLUS: Bulls Cheer Apple Results, Fed Chairman Nominee
Sun, 05 Nov 2017 15:00:00 +0000
A heavy load of economic data and earnings, led by Apple, dominated the week's business news.
Billionaire Blavatnik weighs big share purchase in Teva Pharm – reports
Sun, 05 Nov 2017 13:25:10 +0000
Billionaire businessman Len Blavatnik is looking to buy a significant stake in debt-ridden Israeli drugmaker Teva Pharmaceutical Industries (TEVA.TA), according to Israeli media reports. Two of Israel's leading financial news outlets, Globes and The Marker, reported on Sunday that Blavatnik has been examining a large share purchase in Teva, whose stock price hit a 17-year low last week after the company again cut its annual profit forecast. A spokesman for Blavatnik's U.S.-based industrial group, Access Industries, declined to comment.
Cramer’s Exec Cut: The Apple effect
Fri, 03 Nov 2017 23:05:00 +0000
Jim Cramer sat down with top executives spanning the market to see how the release of Apple’s iPhone X could impact business.
Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up
Fri, 03 Nov 2017 17:39:05 +0000
Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.
Also on Market Tamer…
Follow Us on Facebook